Objective: To compare two 12-core transrectal ultrasound-guided prostate biopsy schemes in respect to cancer detection rates. Methods: Retrospective, single-center analysis of consecutive patients (n = 897) who underwent prostate biopsy (S1) with all 12 cores from far lateral areas (n = 269) or prostate biopsy (S2) with 6 cores from parasagittal and 6 from far lateral areas (n = 628). Results: Crude cancer detection rates with S1 and S2 were similar (39.0 and 38.9% for the first biopsy and 29.4 and 31.3% for repeated biopsies, respectively). Abnormal digital rectal exam, lower prostate volume and higher prostate-specific antigen (PSA) levels were independently associated with higher odds of cancer detection. Regarding first biopsies (n = 747), there was significant interaction between biopsy scheme and PSA (p < 0.001). Overall, the adjusted odds of cancer detection were higher with S1 (S1/S2 odds ratio = 2.54, 95% CI: 1.12-5.74), but the S1-S2 relationship was conditional on PSA: odds ratios progressively increased with increasing PSA from 0.64 (95% CI: 0.40-1.02) at PSA 5 ng/ml to 39.1 (95% CI: 2.71-566) at 75 ng/ml. Conclusion: Higher PSA levels increase the probability of cancer detection with 12-core prostate biopsies, but relative efficiency of different procedures appeared conditional on the PSA level. Data suggest that PSA levels should be considered in the choice of prostate biopsy sampling scheme.

Keywords:
Biopsy regimen, Prostatic cancer, Prostate-specific antigen , Digital rectal examination
1.
Scattoni V, Raber F, Abdollah F, et al: Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. Eur Urol 2010;57:1-8.
2.
Ravery V, Dominique S, Panhard X, et al: The 20-core prostate biopsy protocol - a new gold standard? J Urol 2008;179:504-507.
3.
Presti JC: Prostate biopsy: current status and limitations. Rev Urol 2007;9:93-98.
4.
Neill MG, Toi A, Lowckwood GA, et al: Systematic lateral prostate biopsy - are there benefits worth the costs? J Urol 2008;179:1321-1326.
5.
McNeal JE, Redwine EA, Freiha FS, et al: Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
6.
Guo CC, Zuo G, Cao D, et al: Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol 2009;22:866-871.
7.
Shinohara K: Improving cancer detection by prostate biopsy: the role of core number and site. Nat Clin Pract Urol 2006;3:526-527.
8.
de la Taille A, Antiphon P, Salomon L, et al: Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the cancer detection rate. Urology 2003;61:1181-1186.
9.
Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J: Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006;175:1605-1612.
10.
Eskew LA, Bare RL, McCullough DL: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997;157:199-202, discussion 202-203.
11.
Guichard G, Larré S, Gallina A, Lazar A, Faucon H, Chemama S, et al: Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1,000 consecutive patients. Eur Urol 2007;52:430-435.
12.
de la Rosette JJ, Wink MH, Mamoulakis C, Wondergem N, ten Kate FJ, Zwinderman K, et al: Optimizing prostate cancer detection: 8 versus 12-core biopsy protocol. J Urol 2009;182:1329-1336.
13.
Scattoni V, Roscigno M, Raber M, Dehò F, Maga T, Zanoni M, et al: Initial extended transrectal prostate biopsy - are more prostate cancers detected with 18 cores than with 12 cores? J Urol 2008;179:1327-1331, discussion 1331.
14.
Rabets JC, Jones JS, Patel A, Zippe CD: Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol 2004;172:94-97.
15.
Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL: Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 2000;163:158-162.
16.
Cicione A, Cantiello F, De Nunzio C, Tubaro A, Damiano R: Prostate biopsy quality is independent of needle size: a randomized single-center prospective study. Urol Int 2012;89:57-60.
17.
McNeal JE, Haillot O: Patterns of spread of adenocarcinoma in the prostate as related to cancer volume. Prostate 2001;49:48-57.
18.
Villers A, McNeal JE, Redwine EA, Freiha FS, Stamey TA: The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J Urol 1989;142:763-768.
19.
Chen MK, Luo Y, Zhang H, Lu MH, Pang J, Gao X: Investigation of optimal prostate biopsy schemes for Chinese patients with different clinical characteristics. Urol Int 2012;89:425-432.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.